TNFRSF9 and neoplasm: Preclinical studies have shown cooperative and even synergistic therapeutic benefit by combining 4-1BB agonists with multiple anti-tumor therapies including IL-12 (176), IFNα (177), vaccination (102, 149, 178–180), as well as various other combinations (99, 101, 141–143).